Sonnet BioTherapeutics. has been granted a patent for compositions that combine an albumin binding domain with a fusion partner, such as a cytokine, enhancing serum half-life for therapeutic use, particularly in oncology. The patent specifically claims an IL-12 albumin binding domain fusion protein. GlobalData’s report on Sonnet BioTherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sonnet BioTherapeutics, Peptide pharmacophores was a key innovation area identified from patents. Sonnet BioTherapeutics's grant share as of June 2024 was 15%. Grant share is based on the ratio of number of grants to total number of patents.
Albumin binding domain fusion protein for therapeutic applications
The granted patent US12006361B2 outlines a novel IL-12 albumin binding domain fusion protein characterized by a specific amino acid sequence identified as SEQ ID NO: 280. The patent claims the fusion protein itself, as well as the nucleic acid that encodes this protein, providing a foundational basis for further applications in biotechnology and therapeutic development. Additionally, the patent includes claims for an expression vector that contains the nucleic acid, which is essential for the production of the fusion protein in various host cells.
Furthermore, the patent details a method for producing the IL-12 albumin binding domain fusion protein. This method involves culturing a host cell that contains either the nucleic acid or the expression vector, under conditions conducive to the expression of the fusion protein. The process culminates in the recovery of the IL-12 albumin binding domain fusion protein, which may have significant implications for enhancing the efficacy of IL-12 in therapeutic contexts. Overall, the claims provide a comprehensive framework for the development and production of this fusion protein, potentially advancing research and treatment strategies in immunology and related fields.
To know more about GlobalData’s detailed insights on Sonnet BioTherapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
